Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody drug conjugate (ADC) that targets...
BAT7104 was designedto inhibit the PD-1/PD-L1 and CD47/SIRP-α pathways. By an “imbalanced” designwith finely tuned binding affinity to CD47 and high affinity to PD-L1, BAT7104is expected to avoid RBC depletion and block CD47 on CD47+/PD-L1+ tumors in...
Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagepharmaceutical company, today announced that dosing has begun in Phase 1clinical study to evaluate the pharmacokinetics, safety, and preliminaryanti-tumor ac...
